Investing.com - GSK plc DRC (NYSE: GSK) reported fourth quarter EPS of $0.73, worse than the analyst estimate of $0.74. Revenue for the quarter came in at $10.2B versus the consensus estimate of $9.61B.
GSK plc DRC's stock price closed at $39.09. It is up 13.50% in the last 3 months and up 10.14% in the last 12 months.
GSK plc DRC saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See GSK plc DRC's stock price’s past reactions to earnings here.
According to InvestingPro, GSK plc DRC's Financial Health score is "great performance".
Check out GSK plc DRC's recent earnings performance, and GSK plc DRC's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar